KalVista Pharmaceuticals

KALV49

$11.28arrow_drop_down0.61%-$0.07

KALV49

$11.28

arrow_drop_down0.61%-$0.07

Performance History

Key Stats
Open	$11.27
Prev. Close	$11.36
EPS	-3.57
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	11.09	11.39
52 Week Range	7.21	16.88

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical need. The company’s lead product candidate is KVD900, an oral plasma kallikrein inhibitor being developed for the treatment of hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and airway. KVD900 has the potential to provide a convenient, effective treatment option for patients with HAE, who currently have limited therapeutic options.

KalVista Pharmaceuticals Inc has a market capitalization of $XXX.XX million, indicating the total market value of the company's outstanding shares of stock. The stock price history of KALV shows the historical prices and trading volume of KALV shares over a certain period of time. Investors can analyze this information to identify trends and patterns in the stock's performance. KALV's 52-week range refers to the lowest and highest prices at which KALV shares have traded over the past year. This range provides investors with an idea of the stock's volatility and potential price movement. Additionally, KALV's day range indicates the range of prices at which KALV shares have traded during a single trading session. This information can be useful for day traders looking to enter or exit positions at specific price levels.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Thomas Andrew Crockett M.B.A.
Headquarters: Cambridge
Employees: 118
Exchange: NASDAQ

add KalVista Pharmaceuticals to watchlist

Keep an eye on KalVista Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is KalVista Pharmaceuticals (KALV) stock price performance year to date (YTD)?

As of the latest data, KalVista Pharmaceuticals (KALV) has a year-to-date price change of -7.16%. Over the past month, the stock has experienced a price change of -4.97%. Over the last three months, the change has been -7.54%. Over the past six months, the figure is 2.17%. Looking at a longer horizon, the five-year price change stands at 6.82%.

help

What is KalVista Pharmaceuticals 's (KALV) price per share?

The current price per share for KalVista Pharmaceuticals (KALV) is $11.28. The stock has seen a price change of -$0.07 recently, indicating a -0.62% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for KalVista Pharmaceuticals (KALV)?

For KalVista Pharmaceuticals (KALV), the 52-week high is $16.88, which is 49.65% from the current price. The 52-week low is $7.21, the current price is 56.45% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is KalVista Pharmaceuticals (KALV) a growth stock?

KalVista Pharmaceuticals (KALV) has shown an average price growth of 0.41% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying KalVista Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

Is KalVista Pharmaceuticals (KALV) a profitable company?

KalVista Pharmaceuticals (KALV) has a net income of -$126.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$140.44M. Furthermore, the EBITDA is -$154.72M.

help

What is the market capitalization of KalVista Pharmaceuticals (KALV)?

KalVista Pharmaceuticals (KALV) has a market capitalization of $490.93M. The average daily trading volume is 11.26, indicating the stock's liquidity and investor engagement.